ストックスクリーナーアプリを入手
4.00
4.17%
0.16
アフターアワーズ：
4.00
前日終値:
$3.84
開ける：
$3.86
24時間の取引高:
915.33K
Relative Volume:
0.53
時価総額：
$507.65M
収益：
$433.14M
当期純損益:
$4.95M
株価収益率:
112.04
EPS:
0.0357
ネットキャッシュフロー:
$6.55M
1週間 パフォーマンス:
+0.76%
1か月 パフォーマンス:
-29.95%
6か月 パフォーマンス:
-17.01%
1年 パフォーマンス:
+14.29%
1日の値動き範囲:
$3.84
$4.10
1週間の範囲:
$3.595
$4.10
52週間の値動き範囲:
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
ORGO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
4.00 | 487.34M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
124.40 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.94 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.33 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.66 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
472.06 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-28 | 開始されました | Lake Street | Buy |
| 2024-02-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-10 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-08-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-08-26 | 再開されました | Credit Suisse | Outperform |
| 2019-05-02 | 開始されました | Credit Suisse | Outperform |
| 2019-04-17 | 開始されました | Oppenheimer | Outperform |
| 2019-04-11 | 開始されました | SunTrust | Buy |
すべてを表示
Organogenesis Holdings Inc (ORGO) 最新ニュース
Analysis Recap: Is Organogenesis Holdings Inc backed by strong institutional buyingJuly 2025 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Macro: Is Organogenesis Holdings Inc a strong growth stockJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
About Us - FinancialContent
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28% - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - yourwyominglink.com
Hedge Fund Bets: Is Organogenesis Holdings Inc benefiting from innovation trendsDay Trade & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - FinancialContent
Europe Advanced Wound Care Market Size, Share Projections 2032 - openPR.com
Published on: 2026-01-13 05:15:38 - baoquankhu1.vn
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth? - Sahm
Organogenesis drops as Medicare to pull skin substitute LCDs (update) - MSN
Is Organogenesis Holdings Inc. (2PQ) stock protected from inflationJuly 2025 Action & Free Technical Pattern Based Buy Signals - Улправда
Is Organogenesis Holdings Inc. stock a buy in volatile markets2025 Top Decliners & Growth Oriented Trade Recommendations - Улправда
What margin trends mean for Organogenesis Holdings Inc. stockIPO Watch & Pattern Based Trade Signal System - Улправда
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis ... - Bluefield Daily Telegraph
News - FinancialContent
ORGOOrganogenesis Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Three rising investors just landed bigger roles at a healthcare PE firm - Stock Titan
Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell? - Defense World
Organogenesis (NASDAQ:ORGO) Shares Down 5%Here's What Happened - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com - Investing.com Australia
Organogenesis Holdings extends leases for Canton facilities through 2032 - Investing.com
Organogenesis Extends Long-Term Leases for Key Facilities - TipRanks
Organogenesis (NASDAQ:ORGO) Shares Gap DownTime to Sell? - MarketBeat
Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision - Investing.com Australia
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision By Investing.com - Investing.com South Africa
Organogenesis stock rises after initiating FDA application for knee arthritis treatment By Investing.com - Investing.com India
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis - Nasdaq
Organogenesis begins FDA rolling review for knee arthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis starts rolling submission for ReNu allograft for knee arthritis - Seeking Alpha
Organogenesis stock rises after initiating FDA application for knee arthritis treatment - Investing.com Nigeria
Organogenesis begins FDA rolling review for knee arthritis treatment - Investing.com
Organogenesis Announces Initiation of Biologics License Application for ReNu® - The Manila Times
Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu® to Address Knee Osteoarthritis Pain - Quiver Quantitative
Biologic treatment for knee arthritis pain begins FDA license bid - Stock Titan
Gains Recap: Is Organogenesis Holdings Inc stock dividend yield sustainableWeekly Gains Report & Fast Gaining Stock Strategy Reports - moha.gov.vn
Net current asset value per share of Organogenesis Holdings, Inc. Class A – BER:2PQ - TradingView — Track All Markets
BTIG reiterates Organogenesis Holdings (ORGO) buy recommendation - MSN
Is Organogenesis Holdings Inc. stock a bargain at current levels2025 Momentum Check & Advanced Technical Analysis Signals - Улправда
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO - MarketBeat
Organogenesis (NASDAQ:ORGO) Shares Down 3.7% on Insider Selling - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: 47% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Organogenesis Holdings Inc (ORGO) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
大文字化:
|
ボリューム (24 時間):